Evercore ISI analyst Vijay Kumar raised the firm’s price target on Danaher (DHR) to $250 from $245 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have “set the stage for a 2026 Tools play,” the analyst tells investors. In MedTech, the firm’s survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes “have bears watching,” the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Danaher price target raised to $275 from $250 at Guggenheim
- The Week That Was, The Week Ahead: Macro & Markets, Dec. 20
- Marathon Petroleum CFO John Quaid to depart, Maria Khoury to succeed
- Danaher price target raised to $265 from $250 at BofA
- Danaher price target raised to $240 from $230 at Wells Fargo